Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : IKS014 is a potential best-in-class antibody drug conjugate, benefiting from tumour selective activation and release of the cytotoxic agent monomethyl auristatin F (MMAF).
Product Name : IKS014
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
October 23, 2023
Lead Product(s) : IKS014
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : LegoChem Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement provides Iksuda with world-wide rights (excluding Greater China and South Korea) to LCB’s Her2 ADC programme, LCB14. The agreement includes development, regulatory and commercial milestone payments to LCB contingent as well as royalties o...
Product Name : IKS014
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
October 01, 2022
Lead Product(s) : IKS014
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : LegoChem Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : IKS03
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Mirae Asset Capital
Deal Size : $47.0 million
Deal Type : Financing
Iksuda Therapeutics Closes $47 Million Financing Round
Details : Funding will enable progression of IKS03 to first-in-human phase 1 clinical trials. It will also be used to accelerate the Company’s earlier-stage programmes including IKS04 and IKS012 to IND filing.
Product Name : IKS03
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
July 06, 2021
Lead Product(s) : IKS03
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Mirae Asset Capital
Deal Size : $47.0 million
Deal Type : Financing
Reset All
